Search Results - "Fatoki, Raleigh"

Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies by Fatoki, Raleigh Ayoolu, Koehn, Kelly, Kelkar, Amar, Al Hadidi, Samer, Mehra, Nikita, Mian, Hira, Landgren, Ola, Kazandjian, Dickran, Hoffman, James, Sborov, Douglas W, Mohyuddin, Ghulam Rehman

“…The globalization of clinical trials has accelerated recent advances in multiple myeloma (MM). However, it is unclear whether trial enrollment locations are…”
Get full text

Epidemiology Unknown: Developing an Approach to Identify Potential Smoldering Multiple Myeloma Cases by Fatoki, Raleigh A., Carpenter, Diane M., Khan, Adnan, Stevenson, Ryan, Lo, Joan C., Baer, David M.

“…Background Smoldering Multiple Myeloma (SMM) is an asymptomatic clonal plasma cell disorder that identifies patients at risk for progression to Multiple…”
Get full text

Characterization of smoldering multiple myeloma: A population-based cohort study by Fatoki, Raleigh Ayoolu, Khan, Adnan Ahmed, Carpenter, Diane M., Baer, David M.

“…Abstract only e20028 Background: There is increasing interest in characterizing Smoldering Multiple Myeloma (SMM) due to the availability of novel therapies…”
Get full text

Clinical presentation of multiple myeloma by race/ethnicity and Asian subgroup in an integrated healthcare system by Khan, Adnan Ahmed, Fatoki, Raleigh Ayoolu, Carpenter, Diane M., Lo, Joan C., Baer, David M.

“…Abstract only e20012 Background: Several US studies have evaluated ethnic differences in patients with multiple myeloma (MM), but few have focused on…”
Get full text

Early Infection Risk in Newly Diagnosed Multiple Myeloma Patients in the Modern Era by Stevenson, Ryan, Carpenter, Diane M., Khan, Adnan, Fatoki, Raleigh, Rajagopal, Sumanth, Green, Michael M, Nair, Bijay, Baer, David M.

“…Background: Multiple myeloma (MM) is the second most common hematologic malignancy, with an estimated 30,000 new cases in the United States annually. Advances…”
Get full text

Smoldering multiple myeloma progression to multiple myeloma in a community-based population by Fatoki, Raleigh Ayoolu, Carpenter, Diane M., Ramalingam, Nirmala D., Khan, Adnan Ahmed, Nair, Bijay P., Stevenson, Ryan Lloyd, Green, Michael M., Lo, Joan C., Baer, David M.

“…e20015 Background: Few studies have characterized patients with smoldering multiple myeloma (SMM) in ethnically diverse settings and data regarding progression…”
Get full text

P-136: Global myeloma trial participation and drug access in the era of novel therapies by Fatoki, Raleigh, Koehn, Kelly, Kelkar, Amar, Hadidi, Samer Al, Mehra, Nikita, Mian, Hira, Landgren, Ola, Kazandjian, Dickran, Hoffman, James E., Sborov, Douglas, Mohyuddin, Ghulam Rehman

Get full text

SUN-383 Potential Impact of Using Male vs Female T-Scores for BMD Classification in Men by Fatoki, Raleigh A, Ettinger, Bruce, Chandra, Malini, Horiuchi, Kate M, Lo, Joan Chia-Mei

“…Abstract BACKGROUND: Osteoporosis is traditionally associated with post-menopausal women, but up to up to one-third of osteoporosis-related fractures occur in…”
Get full text